Commercial Opportunities from an Aging Population: Epidemiology market and pipeline analysis across seven major indications, evaluates the benefits of marketing to seniors for the pharmaceutical industry. Globally, the number of older people will increase from 606m in 2000 to 1.9bn in 2050 and as a result healthcare needs will increase and drugs will be used for longer. This report analyzes commercial opportunities within the ‘gray market’ and shows how companies can meet these needs and keep company profits high. Current and future growth prospects are examined for pharmaceutical companies to 2008 in seven major indications particularly associated with seniors. These are acute ischemic stroke, Alzheimer’s disease, arthritis, diabetes, male sexual dysfunction, osteoporosis and prostate cancer. Cumulatively, the total value of these markets was approximately $42bn in 2002 and this figure is set to rise dramatically.
(0 items)
